stomach tumors. such solutions were developed by two leading oncologists from russian professor sergei finlyannd oncologist ilya timofeev scientists selected molecules for 6 years until they received this final russian development, a historical inhibitor of fibroblast growth receptors. behind these pseudo-scientific words, the essence of the discovery is to hit right on target, when the patient is no longer helping in such drugs in the world . we found that this target is expressed on stomach cancer cells and on cancer and ovarian cells, which are very common in russia, so the task was to come up with a drug which blocks this target, the innovativeness of this development lies in the fact that the drug binds to certain centers. in this receptor and changes it, the change of this receptor leads to the fact that the tumor cell of the stomach of gastric cancer is not activated and the tumor and metastases die from their start-up, with the support of the fund. skolkov, conducted preclinical studies and the first phase is already on people of the alphabet. administered to 21 russian patients with g